Jaguar Health Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los ingresos de Jaguar Health disminuyan a un ritmo anual de 40.6%, mientras que se prevé que sus beneficios anuales crezcan a un ritmo de 124.7% por año. Se espera que el BPA crezca en un 148.2% al año.
Información clave
124.7%
Tasa de crecimiento de los beneficios
148.24%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 14.6% |
| Tasa de crecimiento de los ingresos | -40.6% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 12 Feb 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • Jun 25
JAGX: Corporate Transactions And Nasdaq Compliance Will Drive Future Upside Repricing
The analyst price target for Jaguar Health is unchanged at $262.50, with analysts pointing to a steady fair value estimate, the same $262.50 valuation input, and slightly adjusted assumptions for revenue growth and profit margin to support their view. What’s in the News for Jaguar Health Jaguar Health is reviewing multiple potential corporate transactions, including mergers, reverse mergers, acquisitions, partnerships, joint ventures and licensing deals, as it works toward clinical completion for a crofelemer-based drug candidate targeting rare intestinal failure diseases.Actualización de narrativa • Jun 06
JAGX: Nasdaq Listing Risk Will Set Up Future Upside Repricing
Narrative Update on Jaguar Health The analyst price target for Jaguar Health has been reduced by $262.50. Analysts point to sharply lower revenue growth expectations and a modestly higher projected profit margin as key reasons for the reset.Actualización de narrativa • May 17
JAGX: Nasdaq Delisting Risk Will Set Up Future Upside Repricing
Analysts have reset Jaguar Health's fair value estimate from $7.50 to $262.50, reflecting a revised view on the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Nasdaq staff issued a delisting notice on May 1, 2026, citing Jaguar Health's publicly held shares of common stock of approximately 401,226 after the 1 for 35 reverse stock split, which is below the 500,000 minimum required for continued listing under Nasdaq Listing Rule 5550(a)(4) (Nasdaq notice).Actualización de narrativa • Apr 25
JAGX: Nasdaq Listing Risk Will Set Up Future Upside Repricing
Analysts have adjusted their price target for Jaguar Health to $7.50, reflecting updated views on the company’s profit margin profile and long term P/E expectations, while keeping fair value and growth assumptions broadly in line with prior estimates. What's in the News Jaguar Health filed its 10-K on April 7, 2026, with auditor RBSM LLP issuing an unqualified opinion.Actualización de narrativa • Apr 10
JAGX: Nasdaq Listing Risk Will Drive Future Upside Repricing Potential
Analysts have adjusted their price target for Jaguar Health to reflect updated assumptions for slower revenue growth, largely unchanged profit margins, and a substantially higher forward P/E multiple. What's in the News Jaguar Health reported that it will be unable to file its next 10-K by the SEC deadline, indicating a delay in required financial reporting (SEC filing announcement).Actualización de narrativa • Mar 27
JAGX: Nasdaq Listing Risk Will Trigger Future Upside Repricing Potential
Analysts now place Jaguar Health's price target at $7.50, consistent with the prior $7.50 view. They cite broadly unchanged fair value, discount rate and revenue growth assumptions, alongside a slightly lower profit margin outlook and a modestly higher future P/E expectation.Actualización de narrativa • Mar 12
JAGX: Nasdaq Listing Risk Will Set Up Potential Upside Repricing
Analysts maintained their $7.50 price target for Jaguar Health, citing a higher discount rate and slightly lower assumed profit margins, partly offset by a higher future P/E assumption, as the key factors in their updated model. What's in the News On March 5, 2026, Nasdaq notified Jaguar Health that its common stock had closed below the minimum US$1.00 bid price for 30 consecutive business days, leaving the company out of compliance with Nasdaq Listing Rule 5550(a)(2) (Key Developments).Actualización de narrativa • Feb 25
JAGX: Short Term Funding Will Support Improved Profitability Expectations
Analysts have reset their price target for Jaguar Health from $28 to $7.50. They now apply a lower discount rate, more moderate revenue growth expectations, slightly tighter profit margin assumptions, and a higher future P/E multiple in their updated model.
Actualización de narrativa • Feb 09
JAGX: Recent Debt Financing Will Support Upside Potential
Analysts have slightly adjusted their fair value estimate for Jaguar Health to US$35.00. This reflects small tweaks to discount rate, revenue growth and future P/E assumptions rather than a major shift in their overall thesis.Actualización de narrativa • Jan 25
JAGX: Near Term Debt Funding And Shareholder Votes Will Support Upside Potential
Analysts have adjusted their price target for Jaguar Health to US$35.00, reflecting updated views on fair value, discount rate, growth assumptions and future P/E that they consider better aligned with the stock's current risk and return profile. What's in the News Jaguar Health entered into a securities purchase agreement on January 6, 2026, for unsecured promissory notes with an aggregate principal amount of US$350,000, carrying 6% annual interest and maturing one month after issuance (Key Developments).Actualización de narrativa • Jan 11
JAGX: Upcoming Debt Funding And Shareholder Votes Will Support Upside Potential
Analysts have slightly adjusted their fair value target for Jaguar Health to US$35.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping the headline price target level unchanged. What's in the News On November 24, 2025, Jaguar Health, Inc.Actualización de narrativa • Dec 26
JAGX: Future Private Placements Will Support Balance Sheet And Upside Potential
Analysts have raised their price target on Jaguar Health to 35.00 dollars, reflecting slightly higher long term revenue growth assumptions and a modestly higher discount rate. Together these factors keep fair value effectively unchanged while acknowledging incremental upside potential.Actualización de narrativa • Dec 12
JAGX: Future Capital Raises Will Strengthen Balance Sheet And Support Upside Potential
Analysts have modestly reduced their price target on Jaguar Health to reflect a lower fair value estimate of 35 dollars from 40 dollars, even as they factor in stronger revenue growth and a higher future price to earnings multiple, partially offset by slightly softer profit margin assumptions and a lower discount rate. What's in the News Jaguar Health closed a private placement transaction on November 24, 2025, further advancing its ongoing capital raising efforts (Key Developments).Artículo de análisis • Aug 29
Slammed 27% Jaguar Health, Inc. (NASDAQ:JAGX) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Jaguar Health, Inc. ( NASDAQ:JAGX ) shares are down a considerable 27% in the...Artículo de análisis • Jul 02
Investors Give Jaguar Health, Inc. (NASDAQ:JAGX) Shares A 43% Hiding
The Jaguar Health, Inc. ( NASDAQ:JAGX ) share price has fared very poorly over the last month, falling by a substantial...
Nueva narrativa • Apr 18
FDA And EMA Fast-Track Approvals Will Advance Orphan Treatments
New collaborations and regulatory approvals could quicken market entry, increase revenue, and improve earnings through enhanced access to global markets for orphan disease treatments.Artículo de análisis • Feb 05
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 30%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shares have had a horrible month, losing 30% after a relatively good period...Artículo de análisis • Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shareholders won't be pleased to see that the share price has had a very rough...Artículo de análisis • Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shares have had a horrible month, losing 27% after a relatively good period...Artículo de análisis • Jul 24
Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Jaguar Health, Inc. ( NASDAQ:JAGX ) shares are down a considerable 55% in the...Artículo de análisis • May 24
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shares have retraced a considerable 49% in the last month, reversing a fair amount...Artículo de análisis • Mar 29
Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth
Jaguar Health, Inc. ( NASDAQ:JAGX ) shareholders are no doubt pleased to see that the share price has bounced 55% in...Artículo de análisis • Jan 22
Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%
Unfortunately for some shareholders, the Jaguar Health, Inc. ( NASDAQ:JAGX ) share price has dived 39% in the last...Artículo de análisis • Jun 10
Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump
To the annoyance of some shareholders, Jaguar Health, Inc. ( NASDAQ:JAGX ) shares are down a considerable 32% in the...Artículo de análisis • Jan 23
Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2027 | 14 | -6 | -4 | -3 | 1 |
| 12/31/2026 | 20 | -2 | 2 | 2 | 1 |
| 3/31/2026 | 30 | -50 | -8 | -8 | N/A |
| 12/31/2025 | 12 | -54 | -24 | -24 | N/A |
| 9/30/2025 | 12 | -40 | -26 | -26 | N/A |
| 6/30/2025 | 12 | -41 | -28 | -28 | N/A |
| 3/31/2025 | 12 | -40 | -30 | -30 | N/A |
| 12/31/2024 | 12 | -38 | -30 | -29 | N/A |
| 9/30/2024 | 10 | -38 | -29 | -29 | N/A |
| 6/30/2024 | 10 | -36 | -29 | -29 | N/A |
| 3/31/2024 | 10 | -38 | -30 | -30 | N/A |
| 12/31/2023 | 10 | -41 | -33 | -33 | N/A |
| 9/30/2023 | 11 | -40 | -33 | -32 | N/A |
| 6/30/2023 | 11 | -44 | -34 | -34 | N/A |
| 3/31/2023 | 11 | -42 | -37 | -35 | N/A |
| 12/31/2022 | 12 | -47 | -35 | -33 | N/A |
| 9/30/2022 | 11 | -54 | -37 | -36 | N/A |
| 6/30/2022 | 8 | -54 | -38 | -37 | N/A |
| 3/31/2022 | 6 | -59 | -36 | -36 | N/A |
| 12/31/2021 | 4 | -53 | -35 | -35 | N/A |
| 9/30/2021 | 5 | -50 | -30 | -30 | N/A |
| 6/30/2021 | 7 | -46 | -24 | -24 | N/A |
| 3/31/2021 | 10 | -42 | -18 | -18 | N/A |
| 12/31/2020 | 9 | -39 | -15 | -15 | N/A |
| 9/30/2020 | 8 | -35 | -14 | -14 | N/A |
| 6/30/2020 | 7 | -39 | -20 | -20 | N/A |
| 3/31/2020 | 5 | -45 | -21 | -21 | N/A |
| 12/31/2019 | 6 | -45 | N/A | -20 | N/A |
| 9/30/2019 | 6 | -48 | N/A | -22 | N/A |
| 6/30/2019 | 6 | -43 | N/A | -16 | N/A |
| 3/31/2019 | 5 | -34 | N/A | -17 | N/A |
| 12/31/2018 | 4 | -32 | N/A | -23 | N/A |
| 9/30/2018 | 4 | -41 | N/A | -23 | N/A |
| 6/30/2018 | 4 | -30 | N/A | -23 | N/A |
| 3/31/2018 | 4 | -24 | N/A | -19 | N/A |
| 12/31/2017 | 4 | -22 | N/A | -10 | N/A |
| 9/30/2017 | 3 | -5 | N/A | -7 | N/A |
| 6/30/2017 | 2 | -14 | N/A | -17 | N/A |
| 3/31/2017 | 1 | -17 | N/A | -15 | N/A |
| 12/31/2016 | 0 | -15 | N/A | -14 | N/A |
| 12/31/2015 | 0 | 5 | N/A | 1 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que JAGX siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que JAGX siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que JAGX siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos de JAGX disminuyan en los próximos 3 años (-40.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos de JAGX disminuyan en los próximos 3 años (-40.6% al año).
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de JAGX se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/13 13:56 |
| Precio de las acciones al final del día | 2026/07/13 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Jaguar Health, Inc. está cubierta por 2 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Robert LeBoyer | Aegis Capital Corporation |
| Christian Orquera | First Berlin Equity Research GmbH |